News
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Valneva SE (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH updates research on Valneva SE, maintaining Buy rating and lowering target price from €4.50 to €4.40 following Q2 results, projecting rebound in gross margin and likelihood of FDA approval for Lyme disease vaccine candidate LB6V -
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Wolford AG announces group results for the period from January to June 2026
Wolford AG announces group results for the period from January to June 2026, showing a stronger earnings performance despite revenue remaining close to the prior year. The transformation program continues towards sustainable profitability